https://doi.org/10.31288/oftalmolzh201554245

Antiviral properties of collagen-based corneal substitute incorporating sustained delivery system for anti-infective peptide LL37

O.I. Buznyk,1 MD, Cand. Sc. (Med), C.-J. Lee,2 PhD, M.M. Islam,3 MSc, N.V. Pasyechnikova,1 MD, Dr. Sc. (Med), M. Griffith, 2 PhD

1 Filatov Institute of Eye Diseases & Tissue Therapy, Ukraine (Odessa), 2 Linkoping University (Linkoping, Sweden), 3 Karolinska Institute (Stockholm, Sweden)

E-mail: a_buznik@bk.ru

Financial disclosure: This research has been partially supported by a grant from the Swedish Institute in Stockholm.

Purpose: To investigate in vitro the anti–Herpes Simplex Virus (HSV)-1 properties of the collagen-based corneal substitute (CCS) incorporating the sustained delivery system for anti-infective peptide (AIP) LL37.

Methods: AIP LL37 was encapsulated into silica nanoparticles (SiNPs) under magnetic stirring. SiNPs with LL37 were then introduced into the CCS at the time of its fabrication by creating interpenetrating networks of type I collagen and phosphorylcholine. The anti-HSV-1 properties of the composite CCS were assessed by counting plaque forming units (PFU).

Results: When the CCS incorporating the SDS for LL37 was added to the culture of human corneal epithelial cells (HCECs), virus concentration in the 24-h and 72-h culture media was less than 50 PFU/mL and 39333.3±9291.6 PFU/mL, respectively.  Concentration of HVS-1 in the 24-h and 72-h culture media for HCECs without CCS-based treatment was 2800±1928.7 PFU/mL and 221666.7±36855.6 PFU/mL, respectively (P24h = 0.039, Р72h = 0.063).

Conclusion: The CCS incorporating the SDS for LL37 was efficacious within 24 h of culture, when used to block the spread of HSV-1 infection in vitro in HCECs. Additionally, the CCS remained efficacious at 24 h and 72 h of culture, when used for the prophilaxis of HSV-1 infection.

Keywords: artificial cornea, sustained delivery system, LL37, herpes simplex virus

 

References

1. Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D. Antibiotic discovery in the twenty-first century: Current trends and future perspectives. J Antibiot (Tokyo). 2010; 63(8):423–430. 
Crossref

2. Lyall DA, Tarafdar S, Gilhooly MJ, Roberts F, Ramaesh K. Long term visual outcomes, graft survival and complications of deep anterior lamellar keratoplasty in patients with herpes simplex related corneal scarring. Br J Ophthalmol. 2012;96:1200-1203.
Crossref

3. Sharma N, Sachdev R, Jhanji V, et al. Therapeutic keratoplasty for microbial keratitis. Curr Opinion Ophthalmol. 2010;21:293-300.
Crossref

4. Islam MM, Mondal D, Griffith M, Buznyk OI. Anti-infective peptide LL37 sustained delivery system – a potential novel treatment method of ocular infections. Report 2. Anti-viral properties of silica nanoparticle encapsulated LL37. Oftalmol Zh. 2014;3:53-7. Ukrainian.
Crossref

5. Buznyk OI, Pasyechnikova NV, Iakymenko SA, Moloda AL, Islam MM, Griffith M. Anti-infective peptide LL37 sustained delivery system – a potential novel treatment method of ocular infections. Report 3. Anti-microbial properties of silica nanoparticle encapsulated LL37. Oftalmol Zh. 2014;5:4-8. In Ukrainian.

6. Gordon YJ, Huang LC, Romanowski EG, et al. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res. 2005;30(5):385–394.
Crossref

7. Izquierdo-Barba I, Vallet-Reg? M, Kupferschmidt N, et al. Incorporation of antimicrobial compounds in mesoporous silica film monolith. Biomaterials. 2009;30(29): 5729-5736.
Crossref

8. Griffith M, Polisetti N, Kuffova L, et al. Regenerative approaches as alternatives to donor allografting for restoration of corneal function. Ocul Surf. 2012;10(3):170-183.
Crossref

9. Fagerholm P, Lagali NS, Merrett K, et al. A biosynthetic alternative to human donor tissue for inducing corneal regeneration: 24-month follow-up of a phase 1 clinical study. Sci Transl Med. 2010;2:46ra61.

10. Liu W., Deng C, McLaughlin CR, et al. Collagen-phosphorylcholine interpenetrating network hydrogels as corneal substitutes. Biomaterials. 2009;30:1551-1559. 

11. Pasyechnikova N, Vit V, Leus M, et al. Collagen-based bioengineered substitutes of donor corneal allograft implantation: assessment and hypotheses. Med Hypothesis Discov Innov Ophthalmol. 2012;1(1):10-13.

12. Buznyk OI, Pasyechnikova NV, Iakymenko SA, Islam MM, Griffith M. Collagen-Based Corneal Substitutes with Incorporated Anti-infective Peptide LL37 Sustalined Deivery System. Oftalmol Zh. 2015;1:110-114.

13. Buznyk OI. Anti-infective peptide LL37 sustained delivery system – a potential novel treatment method of ocular infections. Report 1. Testing of different carriers of LL37.  Oftalmol Zh. 2014;2:17-21. Ukrainian.

14. Araki-Sasaki K,  Ohashi Y, Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci. 1995;36:614-621. 

15. Ejercito PM, Kieff ED, Roizman B. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol. 1968;2:357-364.